Market-Moving News for June 14th
$ADBE
$BPTH
$MOLN
Computer Software: Prepackaged Software
Technology
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ADBE alert in real time by email
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 9/4/2024 | $580.00 → $625.00 | Outperform | Oppenheimer | |
| 6/14/2024 | $570.00 → $580.00 | Neutral → Overweight | JP Morgan | |
| 6/10/2024 | $510.00 | Buy → Hold | Melius | |
| 3/21/2024 | $445.00 | Underweight | KeyBanc Capital Markets | |
| 1/18/2024 | $499.00 | Neutral → Underperform | Exane BNP Paribas | |
| 12/18/2023 | Equal Weight → Overweight | Barclays | ||
| 12/8/2023 | $670.00 → $690.00 | Outperform | BMO Capital Markets | |
| 10/26/2023 | $660.00 | Perform → Outperform | Oppenheimer |
Oppenheimer reiterated coverage of Adobe with a rating of Outperform and set a new price target of $625.00 from $580.00 previously
JP Morgan upgraded Adobe from Neutral to Overweight and set a new price target of $580.00 from $570.00 previously
Melius downgraded Adobe from Buy to Hold and set a new price target of $510.00
8-K - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)
10-Q - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)
6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
SC 13G/A - BIO-PATH HOLDINGS, INC. (0001133818) (Subject)
SC 13G/A - BIO-PATH HOLDINGS, INC. (0001133818) (Subject)
SC 13D/A - MOLECULAR PARTNERS AG (0001745114) (Subject)
Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2024 and provided an update on recent corporate developments. "The third quarter was a particularly productive period for Bio-Path as we initiated our obesity program, which marks the first application of our DNAbilize® platform beyond oncology and highlights i
HOUSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, November 15, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024 and to provide a business overview. To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the P
Preclinical proof-of-concept data supports the potential of CD3 Switch-DARPin platform to activate and boost T cells in the presence of tumor targets only MP0317's ability to activate CD40 in a variety of tumor types further evidenced by comprehensive clinical biomarker analyses ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced the presentation of data pertaining to two programs, including preclinical proof-of-concept for a novel T cell
4 - ADOBE INC. (0000796343) (Issuer)
4 - ADOBE INC. (0000796343) (Issuer)
4 - ADOBE INC. (0000796343) (Issuer)
Stagwell and Adobe to build a modern marketing partnership with expanded Global wins, while launching a three-year innovative joint go-to-market business partnership leveraging each company's unique offerings Stagwell's agencies 72andSunny, Code and Theory, Locaria, Movers+Shakers, National Research Group and more to collaborate for Adobe at a global scale NEW YORK, Oct. 1, 2024 /PRNewswire/ -- Adobe (NASDAQ:ADBE) today appointed Stagwell (NASDAQ:STGW), the challenger network built to transform marketing, as its global lead for creative campaigns and social content for its Digital Media (DMe) business. Leveraging the integrated strengths of five agencies across the network from upstream rese
Atlassian Corporation (NASDAQ:TEAM), a leading provider of team collaboration and productivity software, today announced it is appointing Scott Belsky to its Board of Directors effective August 1, 2024. Scott is the Chief Strategy Officer and Executive Vice President, Design & Emerging Products, at Adobe (NASDAQ:ADBE), a leader in creative, digital document and digital experience technology. "I'm excited for Scott to bring his deep strategy and product experience to our Board. He's built loveable products used by millions of people around the world, and knows how to deliver customer value. Scott understands the tech industry and has a strong pulse for the trends shaping our world. Never h
Company adds proven SaaS public company CHRO, Jeff Harper, and additional senior roles amidst ongoing scale and expansion. AuditBoard, the leading cloud-based platform transforming audit, risk, compliance, and ESG management, today announced it has brought on public SaaS company veteran Jeff Harper as Chief Human Resources Officer (CHRO) to help scale the organization and infrastructure, continue to attract and retain exceptional talent, and steward AuditBoard's award-winning company culture through continued rapid growth. In addition, AuditBoard has appointed two internal leaders to new senior positions to support the next phase of growth and expansion for the business, naming Anthony Pl
4 - ADOBE INC. (0000796343) (Issuer)
https://news.adobe.com/news/news-details/2024/Adobes-Recent-Statement-Regarding-Updated-Federal-Trade-Commission-Complaint-/default.aspx
Whales with a lot of money to spend have taken a noticeably bearish stance on Adobe. Looking at options history for Adobe (NASDAQ:ADBE) we detected 33 trades. If we consider the specifics of each trade, it is accurate to state that 27% of the investors opened trades with bullish expectations and 30% with bearish. From the overall spotted trades, 17 are puts, for a total amount of $1,217,160 and 16, calls, for a total amount of $1,050,651. Expected Price Movements Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $170.0 to $650.0 for Adobe over the recent three months. Volume & Open Interest Development Assessing the vol
Adobe (NASDAQ:ADBE) has outperformed the market over the past 20 years by 9.64% on an annualized basis producing an average annual return of 18.04%. Currently, Adobe has a market capitalization of $246.28 billion. Buying $100 In ADBE: If an investor had bought $100 of ADBE stock 20 years ago, it would be worth $2,798.14 today based on a price of $555.43 for ADBE at the time of writing. Adobe's Performance Over Last 20 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed
Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the third quarter ended September 30, 2024 and provided an update on recent corporate developments. "The third quarter was a particularly productive period for Bio-Path as we initiated our obesity program, which marks the first application of our DNAbilize® platform beyond oncology and highlights i
HOUSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, November 15, 2024 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2024 and to provide a business overview. To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the P
New CEO has driven significant product capabilities, launched new SaaS platform, bolstered the leadership team, and refreshed the brand as company prepares for the AI era CloudBees, one of the world's leading software development platforms, announced today that thousands of developers and industry leaders will convene at DevOps World Virtual 2024 to celebrate 20 years of Jenkins and the future of DevSecOps, and the path forward as the world's businesses invest in cloud transformation and software for the AI era. "The Global 2000 has three key priorities - empower developers, modernize applications securely, and embrace the power of AI in their transformation journey. The reality, however,